Department of Thoracic and Vascular Surgery, University of Ulm, Ulm, Germany.
J Vasc Surg. 2011 Nov;54(5):1303-9. doi: 10.1016/j.jvs.2011.05.020. Epub 2011 Jul 13.
To analyze early technical success and late clinical success after endovascular entry sealing for chronic type B dissection with special emphasis on reintervention, false lumen thrombosis, and aortic remodeling.
Retrospective analysis of a prospective database. From September 1999 to January 2011, 19 patients with chronic type B dissections were treated by endovascular entry sealing. Median age was 60 years. Median time between onset of acute dissection and surgical intervention was 36 (1 to 60) months. Median follow-up was 13 months (1 to 124).
The endografts used were: Medtronic Captivia (5), Medtronic Valiant (5), Gore TAG (6), Gore C-TAG (2), and Cook Zenith (1). In four patients, revascularization of the left subclavian artery was performed prior to entry sealing. Primary technical success rate (entry sealing, absence of type I leak) was 18/19 (94.7%). In-hospital mortality was 0%. Spinal cord injury with persistent paraplegia occurred in 1/19 (5.2%) patients. After a maximal follow-up of 124 months, reinterventions in 9/19 (47.3%) were necessary: distal/proximal extension of stent graft (8), replacement of the aortic arch due to retrograde dissection (1), and open infrarenal aneurysm repair (1). During follow-up, none of the patients died due to stent-related complications.
Endovascular treatment (EVT) in chronic type B dissections has a high technical success rate and low mortality/morbidity. However reintervention rates are not negligible which might reduce the clinical success of EVT. Future investigations should aim at identifying patients who benefit from EVT at better defining the timing of EVT and at determining if entry sealing alone is sufficient.
分析慢性 B 型夹层血管内入路封闭术后的早期技术成功和晚期临床成功,特别强调再干预、假腔血栓形成和主动脉重塑。
回顾性分析前瞻性数据库。1999 年 9 月至 2011 年 1 月,19 例慢性 B 型夹层患者接受血管内入路封闭治疗。中位年龄为 60 岁。急性夹层发病至手术干预的中位时间为 36 个月(1-60 个月)。中位随访时间为 13 个月(1-124 个月)。
使用的内支架分别为:美敦力 Captivia(5 个)、美敦力 Valiant(5 个)、戈尔 TAG(6 个)、戈尔 C-TAG(2 个)和库克 Zenith(1 个)。在 4 例患者中,在入路封闭前进行了左锁骨下动脉再血管化。19 例患者中,18 例(94.7%)达到主要技术成功(入路封闭,无 I 型漏)。院内死亡率为 0%。19 例患者中,1 例(5.2%)出现脊髓损伤伴持续性截瘫。在 124 个月的最大随访中,有 9/19(47.3%)例需要再次干预:支架移植物的远端/近端延伸(8 例)、因逆行夹层而更换主动脉弓(1 例)和开放肾下动脉瘤修复(1 例)。在随访期间,没有患者因支架相关并发症而死亡。
慢性 B 型夹层的血管内治疗(EVT)具有较高的技术成功率和较低的死亡率/发病率。然而,再干预率不容忽视,这可能会降低 EVT 的临床成功率。未来的研究应旨在确定从 EVT 中获益的患者,更好地定义 EVT 的时机,并确定单独入路封闭是否足够。